切换至 "中华医学电子期刊资源库"
高级检索
中华胸部外科电子杂志

中华胸部外科电子杂志 ›› 2018, Vol. 05 ›› Issue (02) : 103 -106. doi: 10.3877/CMA.J.ISSN.2095-8773.2018.02.07

所属专题： 文献；

论著

观察血清异常糖链糖蛋白表达和细胞免疫功能对肺癌预后的影响
任占良1, 侯俊明1,†(), 任小朋1, 张泳1   
  1. 1. 712000　咸阳，陕西中医药大学附属医院胸心外科
  • 收稿日期:2017-12-15 出版日期:2018-05-28
  • 通信作者: 侯俊明

Observation on the effect of abnormal serum glycoprotein expression and cellular immune function on the prognosis of lung cancer

Zhanliang Ren1, Junming Hou1,†(), Xiaopeng Ren1, Yong Zhang1   

  1. 1. Department of Cardiothoracic Surgery, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, China
  • Received:2017-12-15 Published:2018-05-28
  • Corresponding author: Junming Hou
  • About author:
    Corresponding author: Hou Junming, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

任占良, 侯俊明, 任小朋, 张泳. 观察血清异常糖链糖蛋白表达和细胞免疫功能对肺癌预后的影响[J/OL]. 中华胸部外科电子杂志, 2018, 05(02): 103-106.

Zhanliang Ren, Junming Hou, Xiaopeng Ren, Yong Zhang. Observation on the effect of abnormal serum glycoprotein expression and cellular immune function on the prognosis of lung cancer[J/OL]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2018, 05(02): 103-106.

目的

观察血清异常糖链糖蛋白(TAP)表达和细胞免疫功能对肺癌患者预后的影响。

方法

选取2016年1月—2017年5月陕西中医药大学附属医院收治的49例肺癌患者的临床资料，依据治疗方式不同分为观察组(肺癌根治术加术后辅助化疗，n＝28)和对照组(单纯化疗，n＝21)。分别于治疗前及治疗后1、3个月检测两组患者血清TAP表达和细胞免疫功能指标，采用卡氏(KPS)评分评估患者的生活质量。

结果

两组患者治疗前TAP表达阳性率比较，差异无统计学意义(P>0.05)。观察组治疗后1、3个月，TAP表达阳性率均较治疗前显著下降，差异有统计学意义(P<0.05)。对照组治疗后1、3个月，TAP表达阳性率较治疗前无明显变化，差异无统计学意义(P>0.05)。治疗后1、3个月，观察组TAP表达阳性率均显著低于对照组，差异有统计学意义(P<0.05)。观察组治疗后1、3个月，CD4＋/CD8＋比值均较治疗前显著升高，差异有统计学意义(P<0.01)。对照组治疗后1个月，CD4＋/CD8＋比值与治疗前比较无统计学差异(P>0.05)；但治疗后3个月，CD4＋/CD8＋比值较治疗前下降，差异有统计学意义(P<0.05)。治疗后1、3个月，观察组CD4＋/CD8＋比值均较对照组显著升高，差异有统计学意义(P<0.01)。KPS评分显示，观察组治疗后3个月的有效率为57.1%，对照组为38.1%，观察组显著优于对照组，差异有统计学意义(P＝0.007)。

结论

血清TAP和细胞免疫功能可作为评估肺癌预后疗效、复发的指标，具有临床应用价值。

关键词: 肺癌, 异常糖链糖蛋白, 细胞免疫功能, 预后
Objective

To observe the effect of abnormal serum glycoprotein (TAP) expression and cellular immune function on the prognosis of lung cancer patients.

Methods

Clinical data of 49 patients with lung cancer admitted to the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2016 to May 2017 were selected and divided into observation groups (radical surgery plus postoperative adjuvant chemotherapy, n=28) and control group (chemotherapy, n=21) according to treatment methods. Serum TAP expression and cellular immune function were measured before treatment and at the 1st and 3rd months after treatment, and Karnofsky (KPS) functional status scores were also measured.

Results

The positive rates of TAP expression before treatment in the two groups were not statistically significant (P>0.05). The positive rate of TAP expression at the 1st and 3rd months after treatment in the observation group was significantly lower, and the difference was statistically significant (P<0.05); while the positive rate of TAP expression in the control group showed no statistically significant difference before and after treatment (P>0.05). At the 1st and 3rd months after treatment, the positive rate of TAP expression in the observation group was significantly lower than that in the control group, and the difference was statistically significant (P<0.05). In the observation group, the ratio of CD4+ /CD8+ was significantly increased at the 1st and 3rd months after treatment (P<0.01). While the ratio in the control group at the 1st month after treatment showed no statistically significant difference (P>0.05), but at the 3rd month the ratio lowered significantly (P<0.05). At the 1st and 3rd months after treatment, the ratio of CD4+ /CD8+ in the observation group was significantly higher than that in the control group, and the difference was statistically significant (P<0.01). The KPS score showed that at the 3rd month after treatment the effective rate was 37.1% in the observation group, and 38.1% in the control group. The effective rate in the observation group was significantly better than that in the control group, the difference was statistically significant (P=0.007).

Conclusions

Serum TAP and cellular immune function can be used as indicators to evaluate prognosis and recurrence of lung cancer and have clinical application value.

Key words: Lung cancer, Abnormal glycoprotein, Cellular immune function, Prognosis
表1 两组患者治疗前后TAP表达比较[n(%)]
组别 阳性 弱阳性 阴性
治疗前 ? ? ?
? 观察组(n＝28) 19(67.9) 6(21.4) 3(10.7)
? 对照组(n＝21) 15(71.4) 2(9.5) 4(19.1)
? χ2值 ? 1.647 ?
? P值 ? 0.439 ?
治疗后1个月 ? ? ?
? 观察组(n＝28) 11(39.3) 11(39.3) 6(21.4)
? 对照组(n＝21) 17(81.0) 1(4.8) 3(14.3)
? χ2值 ? 9.819 ?
? P值 ? 0.007 ?
治疗后3个月 ? ? ?
? 观察组(n＝28) 6(21.4) 9(32.1) 13(46.4)
? 对照组(n＝21) 12(57.1) 3(14.3) 6(28.6)
? χ2值 ? 6.716 ?
? P值 ? 0.035 ?
表2 治疗前后免疫功能指标CD4＋/CD8＋的变化情况(±s)
组别 治疗前 治疗后1个月 治疗后3个月
观察组(n＝28) 1.07±0.15 1.57±0.23 1.78±0.54
对照组(n＝21) 1.11±0.36 1.28±0.41 0.86±0.49
t值 0.531 －4.557 －6.137
P值 0.598 0.000 0.000
1
钱桂生．为提高我国呼吸系统疾病的诊治水平而努力[J/CD]．中华肺部疾病杂志：电子版，2012，5(1):1-3.
2
许钰杰，张毅，邝先奎，等．肺癌患者化疗前后T细胞抑制性分子的研究[J]．中国肿瘤临床，2013，40(16):960-964.
3
施南峰．肿瘤异常蛋白(TAP)筛查早期恶性肿瘤应用研究[J]．中国公共卫生管理，2010，26(2):187-189.
4
廖世奇，万波，曾家豫. 肺癌血清肿瘤标志物及其检测方法研究进展[J]．甘肃医药，2013，32(11):826-829.
5
何萍，徐昌维，单喜花，等. 肿瘤异常蛋白对肺癌患者近期疗效的意义[J]．河北中医，2014，36(12):1915-1916.
6
赵先文，江波，韩存芝．大肠癌患者血清肿瘤标志物含量测定与临床研究[J]．中华肿瘤杂志，2005，27(5):286-288.
7
Liu J, Huang XE. Clinical application of serum tumor abnormal protein from patients with gastric cancer[J]. Asian Pac J Cancer Prev, 2015, 16(9): 4041-4044.
8
曹奎杰，刘燕婕. 卵巢上皮癌患者ABO血型抗原表达异常与血清糖链蛋白水平的关系[J]．中华检验医学杂志，2010，33(3):267-268.
9
Granger CL, Parry SM, Denehy L．The self-reported Physical Activity Scale for the Elderly (PASE) is a valid and clinically applicable measure in lung cancer [J]．Support Care Cancer, 2015, 23(11):3211-3218.
10
张志军，张永平，景建闯. 不同麻醉及镇痛方法对肺癌患者T细胞影响[J]．中国公共卫生，2014，30(7):978-980.
11
Hu CY, Zhang YH, Wang T, et al. Interleukin-2 reverses CD8(＋) T cell exhaustion in clinical malignant pleural effusion of lung cancer [J]. Clin Exp Immunol, 2016, 186(1): 106-114.
12
吴姗姗，严峰，邓玉玲，等．小细胞和非小细胞肺癌晚期患者CD3＋CD4＋及CD3＋CD8＋T淋巴细胞亚群的差异[J]．中国免疫学杂志，2015，31(1):114-116,121.
13
王桂枝，秦文华. 化疗对肿瘤患者淋巴细胞亚群的影响[J]．中华全科医学，2009，12(7):1307-1308.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[8] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[9] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[11] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[12] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[13] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号